Precision Announces Dosing of First Patient
Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS® genome editing platform, announced today it has dosed the first patient in the Phase 1/2a clinical trial of PBCAR0191,…
LCMS Plus is now DaVinci Education
PTA president-turned-Durham CEO channels Leonardo Da Vinci with new brand April 8, 2019 Durham, NC — The company behind the online platform that supports leading healthcare education programs — including seven of the country’s top-ranked…
Realtime Robotics Shipping RapidPlan Motion Planning Processor
Realtime Robotics, a Boston-based startup that recently outgrew its space at MassRobotics, announced at Automate 2019 it is now shipping its RapidPlan collision-free motion planning processor. RapidPlan is designed to enable industrial and collaborative robots to…
AskBio Partners with TPG and Vida Ventures
Leading gene therapy company announces $235 million investment to accelerate growth. Asklepios BioPharmaceutical, Inc (AskBio), a developer and manufacturer of Adeno-Associated Virus (AAV) gene therapy therapeutics for underserved patient populations with rare and generally untreatable…
Introducing IndieBio Class Eight
IndieBio are excited to announce their eighth class. IndieBio invests in revolutionary technologies for human and planetary health, and each of these companies, though small today, has tremendous potential to become a very significant and…
PhaseBio Receives FDA Breakthrough Therapy Designation
PhaseBio Pharmaceuticals, based in Malvern, Penn. and San Diego, announced that its antiplatelet drug PB2452 had received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA). PB2452 is a novel, recombinant, human monoclonal antibody antigen-binding fragment…
Honor Recognizes Humacyte’s Progress in Producing Vascular Conduits
Humacyte, an innovator in biotechnology and regenerative medicine, received the Medical Technology Enterprise Consortium (MTEC) Large Project Prototype of the Year Award, in recognition of the development of its human acellular vessel (HAV). The MTEC…
Precision BioSciences Announces Closing of IPO
Duke start-up, Precision BioSciences, has closed its initial public offering of 9,085,000 shares of common stock at a public offering price of $16.00 per share, for total gross proceeds of approximately $145.4 million. This includes…
Humacyte Turns Acellular Vessels into Living Blood Vessels
Science Translational Medicine Publishes Results That Humacyte’s “Human Acellular Vessels Recellularize and Evolve into Living Blood Vessels following Human Implantation” RESEARCH TRIANGLE PARK, N.C. –March 27, 2019 – Humacyte is an innovator in biotechnology and…